Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID 19: A Phase IIa Trial.

Jennifer Sasson,Alexandra N Donlan,Jennie Z Ma,Heather Haughey,Rachael Coleman,Uma Nayak,Amy J Mathers,Patrick E H Jackson,Scott K Heysell,Jeffrey M Sturek,William A Petri

medRxiv : the preprint server for health sciences（2022）

引用 2|浏览4

暂无评分

摘要

Dupilumab was well tolerated and improved 60-day survival in patients hospitalized with moderate to severe COVID-19. Blockade of type 2 immunity offers promise as a novel treatment for COVID-19.

查看译文

关键词

dupilumab,severe covid,hospitalized patients,treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要